Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis

Tzu Hua Lin, Soo Ok Lee, Yuanjie Niu, Defeng Xu, Liang Liang, Lei Li, Shauh Der Yeh, Naohiro Fujimoto, Shuyuan Yeh, Chawnshang Chang

Research output: Contribution to journalArticle

78 Citations (Scopus)

Fingerprint Dive into the research topics of 'Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds